Meeting
2013 ASCO Annual Meeting
Interim analysis of a phase I/II study of panobinostat in combination with bevacizumab for recurrent glioblastoma.
Authors
Eudocia Quant Lee
Dana-Farber Cancer Institute, Boston, MA
Eudocia Quant Lee , David A. Reardon , David Schiff , Jan Drappatz , Alona Muzikansky , Samantha Hammond , Sean Aaron Grimm , Andrew David Norden , Rameen Beroukhim , Christine Sceppa McCluskey , Andrew S. Chi , Tracy Batchelor , Katrina H. Smith , Sarah C. Gaffey , Mary Gerard , Susan M. Snodgrass , Jeffrey J. Raizer , Patrick Y. Wen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT00859222
Citation
J Clin Oncol 31, 2013 (suppl; abstr 2013)
DOI
10.1200/jco.2013.31.15_suppl.2013
Abstract #
2013
Poster Bd #
2
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.
First Author: Eudocia Quant Lee
Poster
2022 ASCO Annual Meeting
Preliminary results of a phase II study of retifanlimab (PD-1 inhibitor) plus or minus epacadostat (IDO1 inhibitor) in combination with bevacizumab and hypofractionated radiotherapy for recurrent glioblastoma: NCT03532295.
First Author: Jian Li Campian
Poster
2016 ASCO Annual Meeting
Phase I/II study of VAL-083 in patients with recurrent glioblastoma.
First Author: Kent C. Shih
Poster
2022 ASCO Annual Meeting
A phase II, multicenter, single-arm trial of eribulin in patients with bevacizumab-resistant recurrent glioblastoma.
First Author: Masamichi Takahashi